May 19, 2017 / 11:38 AM / in 2 months

BRIEF-Amicus Therapeutics says co on track to report top-line data from essence study during Q3

1 Min Read

May 19 (Reuters) - Amicus Therapeutics Inc

* Says Amicus is on track to report top-line data from essence study during Q3 of 2017

* Amicus Therapeutics announces planned analysis of primary endpoints in Phase 3 epidermolysis bullosa study

* Amicus Therapeutics - completed analysis plan for primary endpoints in blinded Phase 3 clinical study of novel topical medicine SD-101 for epidermolysis bullosa Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below